Evaluates neurological severity in Gaucher disease types 2 and 3 using horizontal saccadic eye movement velocity, cognitive function, myoclonic epilepsy burden, and response to substrate reduction therapy (eliglustat/miglustat).
Use the full interactive calculator below, or